Table 1.
Clinical trials for oral immunization.
| Type of vaccine | Sponsor institution | Stages | Clinical registration | Time |
|---|---|---|---|---|
| Live attenuated Shigella vaccine | University of Maryland | Phase 1 | NCT01531530 | 2012 |
| Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine | TD Vaccines A/S | Phase 1 | NCT00901654 | 2009 |
| Live attenuated typhoid vaccine | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 | NCT01019083 | 2009 |
| Live attenuated cholera vaccine | International Vaccine Institute | Phase 2 | NCT00741637 | 2008 |
| Live attenuated Shigella sonnei vaccine | NIAID | Phase 1 | NCT01336699 | 2011 |
| Live attenuated Salmonella vaccine | University of Maryland | Phase 1 | NCT01129453 | 2010 |
| Live attenuated Shigell a vaccine | PATH | Phase 1, | NCT02934178, | 2016 |
| Phase 1 | NCT01813071 | 2013 | ||
| Live attenuated HRV vaccine | National Institute of Hygiene and Epidemiology, Vietnam | Phase 2 | NCT0137757169 | 2011 |
| Live attenuated typhoid fever vaccine | Avant Immunotherapeutics | Phase 2 | NCT00498654 | 2007 |
| Live attenuated ETEC–cholera vaccine | NIAID | Phase 1 | NCT0065410870 | 2008 |
| Adenoviral Norovirus vaccine | Vaxart, Inc. | Phase 1, | NCT02868073, | 2016 |
| Phase 1 | NCT03125473 | 2017 | ||
| Adenoviral influenza vaccine | Vaxart, Inc. | Phase 1, | NCT02547792, | 2015 |
| Phase 1 | NCT0168829771 | 2012 | ||
| Adenovirus vaccine | PaxVax, Inc. | Phase 1 | NCT03160339 | 2017 |
| Replication-competent adenovirus HIV vaccine | PaxVax, Inc. | Phase 1 | NCT02771730 | 2016 |
| Replicating Ad26-vectored HIV-1 vaccine | International AIDS Vaccine Initiative | Phase 1 | NCT02366013 | 2015 |
| Adeonoviral RSV vaccine | Vaxart | Phase 1 | NCT02830932 | 2016 |
| Inactivated cholera vaccine | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 1 | NCT01019083 | 2009 |
| Inactivated polio vaccine | Bilthoven Biologicals | Phase 3 | NCT02766816 | 2016 |
| Inactivated Shigella vaccine | PATH | Phase 1 | NCT01509846 | 2012 |
| Inactivated cholera vaccine | International Centre for | Phase 2, | NCT02742558, | 2016 |
| Diarrhoeal Disease Research, Bangladesh | Phase 1/2 | NCT02823899 | 2016 | |
| Inactivated enterotoxigenic Escherichia coli (ETEC) vaccine | U.S. Army Medical Research and Materiel Command | Phase 3 | NCT02556996 | 2015 |
| Inactivated Vibrio cholerae vaccine | EuBiologics Co.,Ltd | Phase 1 | NCT0170753772 | 2012 |
| Live attenuated/inactivated cholera vaccine | University of Maryland | Phase 2 | NCT02145377 | 2014 |
| Recombinant Helicobacter pylori vaccine | Jiangsu Province Centers for Disease Control and Prevention | Phase 3 | NCT0230217073 | 2014 |
| HIV-1 MN peptide vaccine | NIAID | Phase 1 | NCT00000798 | 2001 |
| Avian influenza DNA vaccine | Vaxart | Phase 1 | NCT0133534774 | 2011 |
HRV, human rotavirus; RSV, respiratory syncytial virus; ETEC, enterotoxigenic Escherichia coli; NIAID, National Institute of Allergy and Infectious Diseases.